Mental health trust exits special measures status
A mental health trust that was once the worst performing in the country has been removed from its "special measures" status after more than seven years, following improvements.
The Norfolk and Suffolk NHS Foundation Trust (NSFT) said it had exited the Recovery Support Programme that helps failing providers.
The decision followed a period of sustained improvement, said NHS England, and the trust's chair Zoe Billingham said it had "achieved stability".
However, campaigners for better mental health care have questioned the decision.
The trust, which is headquartered in Hellesdon, Norwich, was the first of its type to receive extra support back in 2015 when it was placed in "special measures" - the precursor to the Recovery Support Programme.
This grade was removed the following year, but the trust returned to special measures in 2017 because of its poor performance.
NSFT had been rated "inadequate" on four occasions in eight years by Care Quality Commission (CQC) inspectors, with its most recent rating in February 2023 stating it "requires improvement".
Ms Billingham said: "We have now achieved stability; we have a clear plan; the means for delivery; and the belief that we can change NSFT once and for all, for the better."
Caroline Donovan, chief executive at the trust, added: "There truly is so much that has been achieved by everyone last year and so much to feel optimistic about in 2025.
"We can see the impact on service users already, with more positive comments about our services; our friends and family test results have improved; waiting times have significantly reduced in some areas; and our performance is improving."
NSFT will move from mandated national intensive support to mandated regional support and oversight.
Clare Panniker, regional director for NHS England, said it was "positive news" for patients, but there was still much work to do.
"NHS England will ensure that these improvements are built upon at pace to further improve the service NSFT provide," she said.
Chair of the NSFT Crisis Campaign, Mark Harrison, said: "The campaign has no confidence in NHS England as they have presided over 12 years of failing mental health services.
"We don't understand how NSFT can be released from the Recovery Support Programme ahead of an independent inspection from the CQC."
The CQC said NHS England could include its previous reports when removing trusts from the programme. NSFT said it had completed 100% of the CQCs "must do" actions.
The trust said it reviewed 12,503 deaths that had occurred between April 2019 to April 2023, and found just over 420 people died from unexplained unnatural deaths during this period.
There are no national mortality figures for England to compare the figure to.
It also "believes that NSFT are not an outlier across mental health trusts throughout the country".
Of the unexplained unnatural deaths, the predominate demographic is males between the ages of 40 to 50.
In a joint statement, the Labour MPs for Norwich North and Ipswich, Alice Macdonald and Jack Abbott, said: "For the best part of a decade, the Norfolk and Suffolk NHS Foundation Trust has failed thousands of people, with terrible consequences.
"This news that NSFT has left special measures marks some welcome progress, but the challenge for NSFT is now to ensure this is a first step towards sustained, long-term improvement."
The statement continued: "It remains the case that many people in our region are yet to feel this progress in their lived experience of mental health care, with many still recounting tragic personal stories of institutional failure."
Follow Norfolk news on BBC Sounds, Facebook, Instagram and X.
Mental health campaigners to meet MPs
Trust failed to heed safety warnings, campaigners say
NHS trust lost track of patient deaths, review finds
Care Quality Commission
Norfolk and Suffolk Foundation NHS Trust
Norfolk and Suffolk Mental Health Crisis Campaign
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
12 hours ago
- Medscape
NHS England Extends Cervical Screening to 5 Years for Many
From July, women in England aged 25 to 49 who test negative for human papillomavirus (HPV) will be invited for cervical screening every 5 years instead of every 3 years. NHS England said the updated screening schedule would provide women with a more personalised approach based on individual risk. The change follows a recommendation from the UK National Screening Committee and aligns with the current schedule for women aged 50 to 64 in England, as well as screening programmes in Scotland and Wales. Evidence Supports Longer Interval NHS England highlighted that studies have shown that people who test negative for HPV are extremely unlikely to develop cervical cancer within the next decade. Research led by King's College London and published in The BMJ in 2022 found that 5-yearly screening for HPV-negative women was as safe as 3-yearly screening. The study reported no difference in the number of cancers detected and confirmed that less frequent testing was needed. Women who test positive for HPV, with or without abnormal cell changes, will continue on shorter recall. Those with no cell changes will be invited for re-screening in one year, while HPV-positive women with cell changes will be referred for colposcopy. Women will continue to follow the recall schedule advised at their last screening. Only those screened on or after 1 July and meeting the criteria will move to the 5-year interval. Screening Based on Personal Risk Cervical screening was first launched in the UK in 1964. Since 2019, all cervical screening samples collected in England have been tested for high-risk HPV, which is more accurate than the previous method of cytology testing. Cervical cancer is the 14th most common cancer in the UK, with around 3300 new cases each year – nearly all of which are caused by HPV. Since 2008, girls in school year 8 have been offered a vaccine against certain strains of HPV. The programme was extended to boys in 2019. Evidence shows that the vaccine has reduced cervical cancer rates by 90% in England. In Scotland, there have been no recorded cases among vaccinated women since the schools' programme was introduced for girls in 2008. Michelle Mitchell, chief executive of Cancer Research UK, said: 'Screening, alongside the roll-out of the HPV vaccine, has seen cervical cancer rates drop by around a quarter since the early 1990s.' Dr Sue Mann, NHS national clinical director for women's health, said: 'Taking a more personalised approach to cervical screening will help ensure everyone eligible can make the most of these life-saving services, while sparing women appointments that they don't need.' Athena Lamnisos, chief executive of The Eve Appeal, said: 'This new guidance is good news for those at low risk, because they will no longer need to go for cervical screening as often.' Digital Reminders Aim to Boost Uptake The NHS has introduced digital invitations and reminders for cervical screening through the NHS App, as part of a new 'ping and book' service to boost uptake. Eligible women will first receive a notification through the app to alert them to book a screening appointment. If not opened, a follow-up text message will be sent. Paper letters will still be used for those who need them. The 2023-2024 NHS Cervical Screening Programme annual report for England found that 68.8% of women aged 25 to 64 were screened within the recommended timeframe, a slight increase from 68.7% the year before. Coverage was highest among women aged 50 to 64 (74.3%) and lowest among those aged 25 to 49 (66.1%). Louise Ansari, chief executive of Healthwatch England, welcomed the move to digital invites. 'Nearly half of the women we polled last year said the ability to book screenings via the app would make them more likely to attend future appointments,' she said.
Time Business News
15 hours ago
- Time Business News
Left Waiting and Losing Hope – How One Patient Found Relief Through Releaf UK When the NHS Couldn't Help
Every weekday, almost 13,000 new mental-health referrals land on NHS desks across the United Kingdom—far more than stretched community teams can absorb. For the people behind those forms the delay is not abstract: it means panic attacks unchecked, sleep lost, jobs at risk and, in the worst cases, lives cut short. This article follows one such patient and examines why catching psychiatric illness early is not only humane but also a hard-nosed economic imperative. Britain's Growing Mental-Health Backlog NHS England processed a record 4.6 million mental-health referrals last year, with typical waits of 12 weeks for an assessment and, in some counties, up to 18 months for specialist talking therapies. The Royal College of Psychiatrists warns that one in three people referred for depression will spiral into crisis if left untreated for more than three months. Behind every statistic is a household coping with sleepless nights, cancelled plans and mounting uncertainty. The Cost of Delay: Survival Rates Under Pressure Timely care can be the difference between recovery and tragedy. A Lancet meta-analysis tracking 34,000 adults found that evidence-based treatment within six weeks of diagnosis cut suicide attempts by 45 percent over two years. For first-episode psychosis, the National Institute for Health and Care Excellence reports a 50 percent improvement in five-year survival when therapy begins within 14 days of referral. These findings highlight how crucial timeliness is to well-being in healthcare, as every extra week on the waiting list chips away at a patient's odds of staying alive. Productivity on the Line: Why Business Leaders Should Care Delays also drain the balance sheet. Deloitte's 2024 UK Mental-Health Report calculated that poor mental health cost employers £59 billion in absenteeism, presenteeism and staff turnover—nearly £1,800 per employee. Organisations that installed early intervention programmes, such as on-site counselling or rapid referral partnerships, saw an average 5:1 return on investment. In manufacturing alone, stress-related absences translate to 12.7 million lost working days each year—enough to halt the entire aerospace sector for four straight weeks. Emma's Story: Fourteen Months in Limbo Emma Hughes, a 29-year-old graphic designer from Leicester, illustrates the human toll. After a sudden bereavement she developed severe anxiety, intrusive thoughts and chronic insomnia. Her GP referred her for cognitive behavioural therapy (CBT), but the confirmation letter warned of a '40–60-week wait.' Deadlines slipped; sick notes piled up; her self-confidence collapsed. 'Each morning started with a panic attack,' she remembers. By month ten she had exhausted paid leave and faced redundancy. 'I felt invisible—like no one believed how bad it was.' Discovering an Alternate Route Searching for private options, Emma found Releaf's psychiatric care pathway ( a Care Quality Commission-registered clinic offering multidisciplinary assessments within days. Unlike many self-pay services that focus narrowly on prescriptions, Releaf pairs consultant psychiatrists with therapists, nutritionists and sleep specialists. Emma's team designed a stepped-care plan: CBT delivered over secure video, structured sleep-hygiene coaching and, when conventional anxiolytics caused intolerable side-effects, a physician-supervised trial of adjunctive cannabis therapy—a form of cannabinoid treatment tailored to her needs. Six weeks later her sleep stabilised at seven hours a night; by week twelve she had returned to 80 percent of her billable workload. Data on Early Intervention and Workplace Recovery Emma's rapid turnaround echoes wider research. The Centre for Mental Health shows that people receiving comprehensive care within two months of diagnosis are twice as likely to hold a full-time job a year later compared with those who wait more than six months. Replacement costs compound the burden: the Chartered Institute of Personnel and Development pegs the expense of replacing a professional-level employee at £30,600, excluding lost expertise. Early psychiatric care therefore functions as a productivity safeguard, not merely a welfare spend. The Emerging Role of Complementary Therapies Selective serotonin reuptake inhibitors (SSRIs) remain first-line for many disorders, yet growing evidence supports multimodal strategies that include exercise, nutrition and—in specialist settings—medical cannabis for mental health. NICE already endorses cannabinoid medicines for refractory epilepsy and chemotherapy-induced nausea, and pilot studies are exploring benefits for anxiety-related insomnia. For patients like Emma, whose genetics or side-effects rule out standard pharmacology, these adjuncts can mean the difference between chronic disability and daily function. What Swift Access Could Mean for the UK Economy If the NHS achieved its own 28-day referral-to-treatment goal for common mental disorders, economists at the Institute for Public Policy Research estimate a productivity gain of £7.4 billion annually—enough to fund 35,000 additional psychiatric nurses. Meeting that benchmark will require a mixed-economy model in which accredited private providers, including specialized facilities like an addiction treatment center, absorb overflow demand and employers view mental-health budgets as investments. Releaf's rapid-access pathway shows how nimble, multidisciplinary care can slot into that ecosystem, sparing patients the agony of delay and easing pressure on public services alike. TIME BUSINESS NEWS
Yahoo
16 hours ago
- Yahoo
Weight-loss jabs could soon be among most commonly used NHS drugs, top doctor says
Weight-loss jabs could soon become among the most commonly used drugs, the NHS's top doctor has said. Professor Sir Stephen Powis said cheaper versions of the jabs, such as Mounjaro, could lead to widespread use and be as transformative as statins - one of the most highly prescribed drugs taken by around 7 million people in the UK. His comments come as the NHS prepares to roll out access to Mounjaro, also known as tirzepatide, in GP practices. Prof Powis told the NHS ConfedExpo conference the NHS needs to go 'further and faster' to 'turn the tide' on rising levels of obesity and said the drugs could one day be accessed in pharmacies. The outgoing medical director of NHS England told reporters the weight-loss jabs could also be targeted at patients waiting for operations who cannot have them due to their weight. But the government's chief medical officer, Professor Chris Whitty, warned the jabs would not be a 'get out of jail card' for public and social health measures. He told the conference: 'They're not a get out of jail card, which means we don't have to do other social things. It is unacceptable, for example, to be advertising obviously obesogenic foods to young children, on the basis of subsequently they might be able to have jabs to undo the damage which will otherwise be lifelong.' An estimated 1.5 million are taking weight loss jabs in the UK. The Independent recently reported on a case of a woman who was refused a hip operation due to her weight, who had been forced to pay privately for the jabs as she struggled to access them through the NHS. Later this month, GPs in England will be allowed to prescribe Mounjaro for the first time. Patients previously needed to access the drugs through a special weight loss service. Prof Powis hailed the rollout in GP surgeries as an 'exciting milestone' and said NHS officials are also examining ways to 'broaden access to the drugs', such as through pharmacies and digital services. Around 29 per cent of adults in the UK are obese. Prof Powis said: 'Right now, obesity is estimated to cost the NHS approximately £11.4 billion every year – this financial burden is unsustainable for the NHS and wider economy. 'We have to turn the tide. We have to and will go further, and faster. 'In just a few years from now, some of today's weight loss drugs will be available at much lower cost. This could completely transform access to these innovative treatments. He said eventually there would be more drugs coming onto the market, which means prices would likely fall. He said: 'We have been through this with statins, and the use of statins is now very different from when they first came out, and I've no doubt that will be the same for these drugs.' 'So I think over time it's highly likely that they will become more widespread, the evidence base will increase, we will learn better how to deploy them, we'll learn how long people need to be on them, and in terms of weight reduction, how much weight reduction is maintained once people come off – that's a big unknown,' he said. But he said he was not 'starry-eyed' about weight loss drugs, adding they are 'no silver bullet'. He told reporters: 'These medicines can be harmful if they are prescribed without the right checks and wraparound care – they can have side effects, including nausea, dehydration and inflammation of the pancreas, and a worrying number of people are continuing to access them without appropriate checks via the internet. Around 220,000 people are expected to benefit from the rollout of jabs at GP services over the next three years.
